Radiopharmaceutical firm Syncor International received 510(k) clearance from the Food and Drug Administration last month for its iodine-125 seeds, the company’s first product in a line of radioactive implants for treatment of prostate cancer.
Radiopharmaceutical firm Syncor International received 510(k) clearance from the Food and Drug Administration last month for its iodine-125 seeds, the companys first product in a line of radioactive implants for treatment of prostate cancer.
Woodland Hills, CA-based Syncor began to develop the seeds seven months ago, and will market its brachytherapy seed products in the U.S. under the trade name PharmaSeed, according to Robert Funari, president and CEO. In the pipeline is a product using palladium-103, for use with more aggressive tumors.
In other Syncor news, the company plans to begin a stock repurchase program it announced in July. Syncor has 500,800 shares authorized for purchase. When it will begin buying shares and how many it will buy has not been determined.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.